Development of osteogenic chitosan/alginate scaffolds reinforced with silicocarnotite containing apatitic fibers
Abstract
Porous composite scaffolds of chitosan-alginate (CH-AL) reinforced by biphasic calcium phosphate fibers containing silicon (Si) were prepared using the freeze-drying method. The fibers were synthesized using a homogenous precipitation method with differing reaction times and were characterized by XRD, FTIR, SEM, and ICP-OES. Fibers produced with no Si incorporation using two different reaction times of 4 d and 8 d comprised two phases of hydroxyapatite (∼93-96 wt%) and β-tricalcium phosphate (β-TCP). No new phases were observed by adding 0.8 wt% of Si during 4 d of precipitation. However, the addition of Si to fibers synthesized within 8 d under reflux conditions produced biphasic fibers with 1.9 wt% Si which consisted of a new phase of silicocarnotite (∼94 wt%) associated with the β-TCP phase. The whisker-like fibers were 10-200 µm in length and 0.2-5 µm in width. The physicochemical, mechanical, and biological properties of composite scaffolds fabricated by adding different fiber contents and types were investigated. The scaffolds exhibited favorable microstructures with a high porosity (66-88%) and the interconnected pores varied in size between 40 and 250 µm. Scaffolds containing silicocarnotite showed a significant improvement in their mechanical properties and in vitro bioactivity (using SBF testing and characterization of the apatite layer by ATR-FTIR and SEM/EDS) as well as proliferation, mineralization and adhesion of MG63 cells, when evaluated by MTT assay,…
How strong is the evidence?
Evidence Hub reads this as a experimental / empirical study, done in cell cultures (in vitro), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.